Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells

@article{Fay2005LongtermOI,
  title={Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells},
  author={Joseph W. Fay and A Karolina Palucka and Sophie Paczesny and Madhav V Dhodapkar and Dennis A. Johnston and Susan Burkeholder and Hideki Ueno and Jacques Banchereau},
  journal={Cancer Immunology, Immunotherapy},
  year={2005},
  volume={55},
  pages={1209-1218}
}
Between March 1999 and May 2000, 18 HLA-A*0201+ patients with metastatic melanoma were enrolled in a phase I trial using a dendritic cell (DC) vaccine generated by culturing CD34+ hematopoietic progenitors. This vaccine includes Langerhans cells. The DC vaccine was loaded with four melanoma peptides (MART-1/MelanA, tyrosinase, MAGE-3, and gp100), Influenza matrix peptide (Flu-MP), and keyhole limpet hemocyanin (KLH). Ten patients received eight vaccinations, one patient received six… CONTINUE READING
39 Citations
67 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 67 references

The natural history of melanoma and factors predicting outcome

  • C Balch, S Soong, J Thompson
  • 2004
1 Excerpt

Similar Papers

Loading similar papers…